KRAS and malignant colon neoplasm: A further aspect to be taken into consideration in colon cancer is the treatment with 4-hydroxytamoxifen, a selective ER modulator widely used in the therapeutic and chemo-preventive treatment of breast cancer, that caused the degradation of KRAS, a protein whose gene appeared often mutated in colon cancer, through autophagy preventing cancer cell growth [87].